References
- O’Connor OA. T-cell lymphomas. Hematology: Basic Principles Practice. 2013;84:1267–1302.e8.
- Vose J, et al. International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–4130.
- Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon (France): IARC Press; 2008.
- Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15:1467–1475.
- Savage KJ. ALK anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. 5496 Blood. 2008;111(12):5496–5504.
- Xing X, Feldman AL. Anaplastic large cell lymphomas: ALK Positive, ALK Negative, and primary cutaneous. Adv Anat Pathol. 2015;22:29–49.
- Castellar R, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124(9):1473–1480.
- Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: Spectrum of disease and rare long-term survivors. JCO. 2013;31(16):1970–1976.
- Stein H, Foss HD, Dürkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96(12):3681–3695.
- Fanale MA, Horwitz SM, Forero-Torres A, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014;32:3137–3143.
- Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma. Blood. 2015;126(1):17–25.
- d’Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093–3099.
- Younes A, Bartlett NL, Leonard JP, et al. Brentuximab Vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812–1821.
- Chen X, et al. Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin. Onco Targets Ther. 2014;7:45–56.
- Chen R, Hou J, Newman E, et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther. 2015;14(6):1376–1384.
- Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012;18(1):248–255.
- Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma:Results of a phase II study. J Clin Oncol. 2012;30:2190–2196.
- O’Connor OA. Phase III trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL). 2015 ASCO Annual Meeting. Abstract No. TPS8605.
- Cao H, Yamamoto K, Yang L-X, et al. Brentuximab vedotin: first-line agent for advanced Hodgkin lymphoma. Anticancer Res. 2013;33(9):3879–3885.
- Forero-Torres A, Bartlett NL, Berryman RB, et al. Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies. Leukemia & Lymphoma. 2015;56(4):1151–1153.